Compile Data Set for Download or QSAR
Report error Found 206 Enz. Inhib. hit(s) with all data for entry = 11802
TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649268(2-Chloro-N-(2-{4-[(6-chloropyridin-2-yl)oxy]piperi...)
Affinity DataIC50: 11.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649300(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 11.3nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649255(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 11.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649217(2-Chloro-N-(2-{4-[(4-chloro-1,3-thiazol-2-yl)oxy]p...)
Affinity DataIC50: 11.8nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649264(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 11.9nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649223(N-{2-[4-(1,3-Benzoxazol-2-yloxy)piperidin-1-yl]-2-...)
Affinity DataIC50: 12.3nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649274(2-Chloro-N-[2-(4-{[(4-chloro-1,3-thiazol-2-yl)oxy]...)
Affinity DataIC50: 13nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649293(2-Chloro-N-[2-(4-{[(3-cyanopyridin-2-yl)oxy]methyl...)
Affinity DataIC50: 13.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649268(2-Chloro-N-(2-{4-[(6-chloropyridin-2-yl)oxy]piperi...)
Affinity DataIC50: 13.4nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649283(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 13.8nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649222(N-{2-[4-(1,3-Benzothiazol-2-yl oxy)piperidin-1-yl]...)
Affinity DataIC50: 14nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649273(2-chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 15.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649284(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 15.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649296(2-Chloro-N-[2-(4-{[(4-cyanopyridin-3-yl)oxy]methyl...)
Affinity DataIC50: 16.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649306(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 16.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649303(2-Chloro-N-[2-(4-{[(3-chloropyridin-2-yl)oxy]methy...)
Affinity DataIC50: 16.4nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649261(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 16.6nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649229(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 17.3nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649222(N-{2-[4-(1,3-Benzothiazol-2-yl oxy)piperidin-1-yl]...)
Affinity DataIC50: 17.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649297(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 17.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649305(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 18.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649305(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 18.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649218(2-Chloro-N-(2-{4-[(3-cyclopropyl-1,2,4-thiadiazol-...)
Affinity DataIC50: 19.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649294(2-Chloro-N-[2-(4-{[(6-cyanopyridin-2-yl)oxy]methyl...)
Affinity DataIC50: 19.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649247(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 19.4nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649247(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 19.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649279(2-Chloro-N-[2-(4-{[(2-cyanopyridin-3-yl)oxy]methyl...)
Affinity DataIC50: 20nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649272(2-chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 20.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649271(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 20.3nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649223(N-{2-[4-(1,3-Benzoxazol-2-yloxy)piperidin-1-yl]-2-...)
Affinity DataIC50: 20.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649288(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 21.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649231(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 21.3nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649206(2-chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 21.7nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649281(2-Chloro-N-[2-(4-{[(3-cyanopyrazin-2-yl)oxy]methyl...)
Affinity DataIC50: 22.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649296(2-Chloro-N-[2-(4-{[(4-cyanopyridin-3-yl)oxy]methyl...)
Affinity DataIC50: 22.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649282(N-(2-{4-[(1,3-Benzothiazol-2-yloxy)methyl]piperidi...)
Affinity DataIC50: 22.7nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649252(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 22.8nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649284(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 22.8nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649253(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 22.9nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649306(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 23nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649215(2-chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 23.5nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649210(2-chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 23.7nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649229(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 24nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649278(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 24.1nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649292(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 24.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649261(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 24.6nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649294(2-Chloro-N-[2-(4-{[(6-cyanopyridin-2-yl)oxy]methyl...)
Affinity DataIC50: 24.9nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649295(2-Chloro-N-[2-(4-{[(2-cyanopyridin-4-yl)oxy]methyl...)
Affinity DataIC50: 25nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Mouse)
Breye Therapeutics

US Patent
LigandPNGBDBM649277(2-Chloro-N-{2-[4-(difluoromethyl)-1,3-thiazol-5-yl...)
Affinity DataIC50: 25.2nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

TargetP2X purinoceptor 7(Human)
Breye Therapeutics

US Patent
LigandPNGBDBM649293(2-Chloro-N-[2-(4-{[(3-cyanopyridin-2-yl)oxy]methyl...)
Affinity DataIC50: 25.6nMAssay Description:Extracellular binding of Bz-ATP to P2X7 receptor opens the channel and allows Ca2+ influx into the cells. This Ca2+ entry was measured in HEK-293 cel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/4/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 206 total ) | Next | Last >>
Jump to: